| Literature DB >> 34479550 |
Ali Amirinejad1, Ali Saneei Totmaj1, Farzaneh Mardali1, Azita Hekmatdoost2, Hadi Emamat3, Majid Safa4, Farzad Shidfar5.
Abstract
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. The aim of this study was to evaluate the effects of hydro-alcoholic extract of spinach (HES) on hepatic and serum measurements of NAFLD in a rat model.Entities:
Keywords: Inflammation; NAFLD; NASH; Oxidative stress; Spinach
Mesh:
Substances:
Year: 2021 PMID: 34479550 PMCID: PMC8418034 DOI: 10.1186/s12906-021-03396-x
Source DB: PubMed Journal: BMC Complement Med Ther ISSN: 2662-7671
The sequence of primers used for gene expression
| Gene Name | Sequences | Accession No. | No. of first and last Nt. | Product length |
|---|---|---|---|---|
| GAPDH-FW | 5′-CCTGTGACTTCAACAGCAACTC-3´ | NM_017008.4 | 917–938 | 177 bp |
| GAPDH-RW | 5′-GGTGGTCCAGGGTTTCTTACTC-3´ | 1072–1093 | ||
| PPAR-γ-FW | 5′-GTTCACAAGAGCTGACCCAATG-3´ | NM_013124.3 | 332–353 | 135 bp |
| PPAR-γ-RW | 5′-TGTGGCCTGTTGTAGAGTTGG-3´ | 446–466 | ||
| TNF-α-FW | 5′-CCAAATGGGCTCCCTCTCATC-3´ | NM_012675.3 | 337–357 | 112 bp |
| TNF-α-RW | 5′-CCGCTTGGTGGTTTGCTAC-3´ | 430–448 | ||
| IL-10-FW | 5′-GCGACGCTGTCATCGATTTC-3´ | NM_012854.2 | 370–389 | 153 bp |
| IL-10-RW | 5′-AGTGTCACGTAGGCTTCTATG C-3´ | 501–522 |
Weight gain, total food intake, serum inflammation and oxidative stress biomarkers, and antioxidant enzyme activity in liver at the end of the prevention phase
| Variables | Control | High-fat | High-fat + Spinach | |
|---|---|---|---|---|
| 94 ± 19.1a | 142.8 ± 26b | 116.1 ± 16.2a | < 0.01* | |
| 152.4 ± 13.9a | 175.8 ± 12.3b | 159.9 ± 8.7a | 0.01* | |
| 139.1 (103–187.5) | 155.6 (128.5–216.5) | 124 (114.9–133.1) | 0.22† | |
| 3 ± 0.5a | 4.1 ± 0.7b | 3.2 ± 0.5a | 0.01* | |
| 0.66 ± 0.09a | 0.84 ± 0.09b | 0.68 ± 0.11a | 0.01* | |
| 0.65 ± 0.1 | 0.74 ± 0.1 | 0.62 ± 0.1 | 0.28 | |
| 227.8 ± 26.9 | 220.3 ± 16.7 | 216.6 ± 22.3 | 0.68 | |
| 228.3 ± 54.2 | 220.8 ± 38.8 | 288 ± 85 | 0.15 | |
| 54 ± 20.7ab | 37.8 ± 14.3a | 65.9 ± 9.4b | 0.02* | |
| 0(0–0.25)a | 2(1–2)b | 1(0–1)a | < 0.01† | |
| 0.5 ± 0.83a | 3.83 ± 1.16b | 2 ± 1.09c | < 0.001* |
Values are expressed as mean ± SD for data with normal distribution and median (IQR) for those with non-normal distribution
CCK = Cholecystokinin, hs-CRP = high-sensitivity C-reactive protein, PTX-3 = pentraxin-3, MMP-9 = matrix metalloproteinase-9, TAC = total antioxidant capacity, GPX = glutathione peroxidase, SOD = superoxide dismutase
Different letters show significant difference at P < 0.05
† Kruskal–Wallis test
Fig. 1Liver gene expression of PPAR-γ, TNF-α, and IL-10 at the end of the prevention phase. Different letters show significant difference at P < 0.05
Weight gain, total food intake, serum inflammation and oxidative stress biomarkers and antioxidant enzyme activity in liver at the end of the treatment phase
| Control | Control+ Spinach | High-fat | High-fat+ Spinach | ||
|---|---|---|---|---|---|
| Weight gain(g) | −22 ± 22a | −22.8 ± 18.4a | 16.8 ± 7.8b | 12.3 ± 10.2b | < 0.001* |
| Food intake(g) | 77.7 ± 5.1a | 82.1 ± 6.4a | 111.5 ± 16.8b | 102.7 ± 7.6b | < 0.001* |
| CCK(ng/l) | 117.5 ± 48.9 | 116.4 ± 29.8 | 127.5 ± 23.1 | 133.8 ± 17.5 | 0.75 |
| Hs_CRP(ng/ml) | 3.48 ± 0.62a | 3.68 ± 0.43a | 4.69 ± 0.96b | 3.68 ± 0.64a | 0.02* |
| PTX-3(ng/ml) | 0.63 ± 0.14a | 0.63 ± 0.09a | 0.86 ± 0.1b | 0.67 ± 0.17a | 0.02* |
| MMP-9(ng/ml) | 0.5 ± 0.09a | 0.52 ± 0.19a | 0.81 ± 0.22b | 0.64 ± 0.17ab | 0.02* |
| TAC(μmol/l) | 214(181.5–219.2)ab | 204(199–216.5)a | 186(180.5–191.2)b | 209(205.5–212)a | 0.03*† |
| GPX(U/ml) | 233.8 ± 33.5a | 365.9 ± 115.7b | 224.6 ± 51.7a | 336.1 ± 86.1b | 0.01* |
| SOD(U/ml) | 56 ± 25.5 | 59.9 ± 14.2 | 44.4 ± 14.6 | 70.7 ± 16.1 | 0.12 |
| Steatosis score | 0(0–0.25)a | 0(0–0)a | 2(1–2)b | 1(0–1)a | 0.001*† |
| NAS score | 1(0–2)a | 1(0–2)a | 4(3–5)b | 2(0–4)ab | 0.007*† |
Values are expressed as mean ± SD for data with normal distribution and median (IQR) for those with non-normal distribution
CCK = Cholecystokinin, Hs_CRP = High-sensitivity C-reactive Protein, PTX-3 = Pentraxin-3, MMP-9 = Matrix metalloproteinase-9, TAC = Total antioxidant capacity, GPX = Glutathione peroxidase, SOD = Superoxide dismutase
Different letters show significantly different at P < 0.05
† Kruskal–Wallis test
Fig. 2Liver gene expression of PPAR-γ, TNF-α, and IL-10 at the end of the treatment phase. Different letters show significantly different at P < 0.05